Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot and main phase study of intravenous MR30507/09 versus MR30365/07, fentanyl, and placebo on respiratory effects in healthy volunteers
NL-OMON39546Phase 1Active, not recruiting
- Sponsor
- Mundipharma
- Start
- Feb 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MR30507/09, oxycodone, fentanyl, naloxone and naltrexone (8 arms), sponsored by Mundipharma. Primary endpoints: Effect of MR30507/09 on ventilation, Dose-response relationship for respiratory effects and 1 more. Started Feb 2013; status: active, not recruiting.
02
Drugs
MR30507/09oxycodonefentanylnaloxonenaltrexone
Beyond the preview
Go deeper on NL-OMON39546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39546.